Targets › HCK
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2028.
Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as…. (UniProt, P08631)
Open in Phaseline: the race on HCK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Baylor College of Medicine | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 2 | Chronic Myeloid Leukemia | Nov 2028 |
| Children's Oncology Group | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 1 | Philadelphia Chromosome Positive CML | Jul 2028 |
Chronic Myeloid Leukemia (1) Philadelphia Chromosome Positive CML (1)
other (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.